Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Alexandra Lindsey Zune Djomkam, Charles Ochieng Olwal, Theodore Beyeme Sala, Lily Paemka

Research output: Contribution to journalComment/debate

47 Citations (Scopus)
Original languageEnglish
Article number1448
JournalFrontiers in Oncology
Volume10
DOIs
Publication statusPublished - 19 Aug 2020

Keywords

  • ACE2
  • COVID-19
  • SARS-CoV-2
  • TMPRSS2
  • coronavirus
  • prostate cancer

Cite this